Aspergillosis
📧 Sign up to get email alerts when something new happens for Aspergillosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-22EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The EMA authorised Voriconazole Accord (voriconazole) for treatment of fungal infections including Aspergillosis, Candidiasis, and Mycoses, …
-
EMA approval · 2026-07-21EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
Pfizer's voriconazole (Vfend) has been authorised by EMA for use in fungal infections including candidiasis, mycoses, and aspergillosis.
-
EMA approval · 2026-07-01EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
EMA authorises Noxafil (posaconazole) for multiple fungal infections including candidiasis, mycoses, coccidioidomycosis, and aspergillosis.
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
-
EMA approval · 2026-04-28EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
European Medicines Agency authorises Vfend (voriconazole) for fungal infections including candidiasis, mycoses, and aspergillosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-22EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
The EMA has granted marketing authorization for Noxafil (posaconazole) by Merck Sharp & Dohme B.V. for the treatment and prevention of funga…
-
EMA approval · 2026-04-14EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Vfend (voriconazole) for fungal infections including candidiasis and aspergillosis.
-
EMA approval · 2026-01-08EMA Authorised: Cancidas (previously Caspofungin MSD) (caspofungin (as acetate))
EMA has authorised Cancidas (caspofungin acetate) for the treatment of candidiasis and aspergillosis.
-
EMA approval · 2026-01-06EMA Authorised: Voriconazole Hikma (previously Voriconazole Hospira) (voriconazole) — Hikma Farmaceutica (Portugal) S.A.
The EMA authorised Voriconazole Hikma for fungal infections, including aspergillosis and candidiasis, with Hikma Farmaceutica (Portugal) S.A…
-
EMA approval · 2025-10-21EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Voriconazole Accord (voriconazole) for treating aspergillosis, candidiasis and other mycoses; the m…
-
EMA approval · 2025-07-24EMA Authorised: Cresemba (isavuconazole) — Basilea Pharmaceutica Deutschland GmbH
The EMA has authorised Cresemba (isavuconazole) for use in Aspergillosis under Basilea Pharmaceutica Deutschland GmbH, with orphan designati…
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
-
FDA approval · 2025-03-12FDA Approved: ITRACONAZOLE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for itraconazole from Ascend Laboratories, LLC, authorizing changes to the generic product under AND…
-
FDA approval · 2025-01-29FDA Approved: ITRACONAZOLE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for itraconazole by Camber Pharmaceuticals, expanding/updating labeling for the generic product.
-
FDA approval · 2024-10-24FDA Approved: ITRACONAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for itraconazole from Alembic Pharmaceuticals Inc., resulting in a label-related approval update for…
-
FDA approval · 2022-11-17FDA Approved: AMPHOTERICIN B — Original Application (Eugia US LLC)
FDA approved the original ANDA for Amphotericin B from Eugia US LLC, authorizing a generic Amphotericin B product.
-
FDA approval · 2022-02-04FDA Approved: POSACONAZOLE — Original Application (Biocon Phama Inc.)
FDA approved Biocon Phama Inc.'s original application for posaconazole, authorizing a generic formulation of the antifungal agent.
-
FDA approval · 2016-09-26FDA Approved: ITRACONAZOLE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for itraconazole, granting a generic version of the antifungal medication. Th…
-
FDA approval · 2015-10-30FDA Approved: ITRACONAZOLE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original ANDA for itraconazole, enabling a generic version of the antifungal agent to be marketed.
-
FDA approval · 2012-06-21FDA Approved: NOXAFIL — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for NOXAFIL (posaconazole) from Merck Sharp & Dohme LLC, indicating an update to the NDA under t…
-
FDA approval · 2010-03-05FDA Approved: AMPHOTERICIN B — Supplemental Application (XGen Pharmaceuticals DJB, Inc.)
FDA approved a supplemental application for Amphotericin B submitted by XGen Pharmaceuticals DJB, Inc. This approval authorizes a change to …
-
FDA approval · 2006-09-15FDA Approved: NOXAFIL — Original Application (Merck Sharp & Dohme LLC)
NOXAFIL (posaconazole) received FDA approval through its original application as a broad-spectrum antifungal agent for the prevention of inv…